Biotechs Under a Buck

[FELLER]

$OWCP - Multiple Myeloma Study UPDATE!

The next phase of the study, which is based upon the promising results of OWC's earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] to best determine the most effective dosages and means of delivery for the future planned study on human patients, pending receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.

Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs of OWC, stated that this unique study, which we designed to pursue and secure FDA orphan designation status, will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time potentially enhance response to various multiple myeloma treatment regimes.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12035254

It's been my opinion for MONTHS that OWCP would rise to several dollars by Q3. Today's share prices are a bargain.